<DOC>
	<DOCNO>NCT00897676</DOCNO>
	<brief_summary>The purpose study examine effect exendin- ( 9-39 ) fast blood glucose protein induce hypoglycemia subject Congenital Hyperinsulinism . Funding Source - FDA OODP .</brief_summary>
	<brief_title>Effect Exendin- ( 9-39 ) Fasting Adaptation Protein Sensitivity</brief_title>
	<detailed_description>This placebo control study randomize crossover design evaluate effect glucagon-like peptide-1 ( GLP-1 ) receptor antagonist , exendin- ( 9-39 ) , fast blood glucose level , protein-induced hypoglycemia , fast tolerance subject congenital hyperinsulinism due mutation ATP- sensitive potassium channel ( KATP ) channel .</detailed_description>
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Congenital Hyperinsulinism</mesh_term>
	<criteria>Confirmed diagnosis hyperinsulinism Mutation analysis result demonstrate KATP channel defect Age 6 month 18 year Persistent hypoglycemia Current therapy medication may affect glucose metabolism octreotide , diazoxide , high dose glucocorticoid , adrenergic agent , etc . Subjects eligible participate last dose octreotide give 48 hr study day 1 last dose diazoxide give 72 hour study day 1 Evidence medical condition might alter result compromised elimination peptide , include active infection , kidney failure , severe liver dysfunction , severe respiratory cardiac failure Pregnancy Subjects milk protein allergy exclude participate study involve protein tolerance test</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hyperinsulinism</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>KATP channel</keyword>
</DOC>